SCHEMBL30325859

SCHEMBL30325859

C=C(F)C(=O)Nc1ccc(-c2nn3ncnc(N)c3c2-c2ccc(C(=O)NCC(F)(F)F)cc2)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RIPK2 O43353 1/20 0.36
▸ NAMPT P43490 1/20 0.34
▸ AURKA O14965 3/20 0.33
▸ RET P07949 3/20 0.33
▸ AURKB Q96GD4 2/20 0.33
▸ BTK Q06187 2/20 0.33
▸ JAK2 O60674 1/20 0.33
▸ JAK1 P23458 1/20 0.33
▸ JAK3 P52333 1/20 0.33
▸ KDR P35968 2/20 0.33
▸ TRPV1 Q8NER1 2/20 0.33
▸ PLK4 O00444 1/20 0.33
▸ DAPK3 O43293 1/20 0.33
▸ ROCK2 O75116 1/20 0.33
▸ PAK4 O96013 1/20 0.33
▸ CHEK2 O96017 1/20 0.33
▸ ABL1 P00519 1/20 0.33
▸ NTRK1 P04629 1/20 0.33
▸ INSR P06213 1/20 0.33
▸ LCK P06239 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30325673 0.88 RET (0.35) AURKARETAURKBBTKJAK3
SCHEMBL30325933 0.88 KDR (0.37) NAMPTAURKARETKDRPLK4
SCHEMBL31213973 0.86 RPS6KB1 (0.31) RIPK2NAMPTAURKAAURKBBTK
SCHEMBL30325676 0.86 RET (0.33) AURKARETAURKBBTKFGFR1
SCHEMBL30325774 0.85 BTK (0.39) BTKFGFR1
SCHEMBL30325937 0.81 PIK3CD (0.34) NAMPTAURKAAURKBBTKKDR
SCHEMBL31213899 0.81 CSF1R (0.36) AURKABTKKDRPLK4DAPK3
SCHEMBL30325665 0.80 BTK (0.37) RETBTK
SCHEMBL30325883 0.80 KDR (0.37) NAMPTAURKARETKDRPLK4
SCHEMBL30325832 0.79 BTK (0.39) BTKFGFR1FGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240383905-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2024-11-21 — — US claimed
EP-4405358-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H Pharmaceuticals Co., Ltd. (CN) 2024-07-31 — — EP claimed
WO-2023046117-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2023-03-30 — — WO claimed
US-20240383905-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2024-11-21 — — US disclosed
EP-4405358-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H Pharmaceuticals Co., Ltd. (CN) 2024-07-31 — — EP disclosed
WO-2023046117-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2023-03-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383905-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF FGFR1, FGFR3, FGFR4 RIPK2 2164/4885NAMPT 814/4885AURKA 210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback